Results 101 to 110 of about 98,807 (272)

Comparison the %IR between gemcitabine and gemcitabine plus cisplatin. [PDF]

, 2019
Comparison the %IR between gemcitabine and gemcitabine plus cisplatin.
Poramate Klanrit (7365617), Attapol Titapun (7365620), Watcharin Loilome (130145), Prakasit Sa-ngiamwibool (7365626), Nisana Namwat (816276), Narong Khuntikeo (415025), Apiwat Jarearnrat (7365623), Anchalee Techasen (816277), Manida Suksawat (7365614), Jutarop Phetcharaburanin (2618605)   +9 more
core   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Wang, X, Jing Chen, Fan Yan, Xin, W, He Ren, Yan, F, Qian, D, Li, J, Hao, J, Wen Xin, Dong Qian, Chongbiao Huang, Jia, L, Song Gao, Jing Li, Chen, J, Huang, C, Zhao, T, Ren, H, Gao, S, Li Jia, Jihui Hao, Tiansuo Zhao, Xiuchao Wang   +23 more
core   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials [PDF]

, 2018
Jiamin Jin, Chunbo Teng, Tao Li College of Life Science, Northeast Forestry University, Harbin, China Purpose: We aimed to compare the efficacy of combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer (PC) by ...
Jin JM, Li T, Teng CB
core  

The current and future burden and cost of overactive bladder in five European countries. [PDF]

, 2006
OBJECTIVE: To estimate and compare the current and future direct cost of overactive bladder (OAB) to the health care systems of five European countries.
Reeves, Penny, Kelleher, Con, Kopp, Zoe, Lloyd, Adam, Irwin, Deb, Milsom, Ian, Calvert, Neill   +6 more
core   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC [PDF]

, 2007
Gemcitabine (2'2'-difluorodeoxycytidine) is a pyrimidine analog used in the treatment of a variety of solid tumors. After intravenous (i.v.) administration, it is rapidly inactivated to 2'-deoxy-2',2'-difluorouridine (dFdU). A sensitive analytical method
Lanz, Christian, Früh, Martin, Thormann, Wolfgang, Lauterburg, Bernhard H, Cerny, Thomas   +4 more
core   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer

Zhongguo aizheng zazhi, 2016
Background and purpose: Breast cancer has the highest morbidity and mortality rate in women worldwide. Triple-negative breast cancer (TNBC) has no specific target and has low survival rate.
陈玉丽, 朱勤伟, 隋晓梅
doaj